Partners
Partners

Partner 29 - Servier


Servier

Prof. Brian Lockhart

 

Principal Investigator

 

undefinedE-Mail

 

 

Institut de Recherces Servier

 

Suresnes Research Center

Rue de la Republique 3

92150 Suresnes

France

undefinedWebsite

Company presentation


The main therapeutic areas for which Servier’s research is renowned are cancer, cardiovascular disease, endocrinology, neuroscience, rheumatology, and venous disease.
30 innovative medicines have been developed from in-house research since the company’s beginnings in 1954, the last three of which are each first of their therapeutic class.
Servier is currently collaborating with approximately 30 public and private research organizations throughout the world, including many biotech companies who chose to work with Servier among a large number of candidate companies.
68% of Servier’s medicines are produced in France. As 90% of Servier medicines are consumed outside France.
The Division of Biotechnology & Biomarker Research is dedicated to the application of technologies and expertise from genomics, proteomics, bioinformatics, cellular imaging and histopathology to the validation of target hypothesis and the discovery, characterization and application of biomarkers in discovery and early clinical development.
Our objective within this consortium is to interact with leading research scientists and clinicians from academic and industrial partners to empower improved standardization, comparison and validation of different methodologies / technologies in liquid biopsy research (CTCs , ctDNA in particular) and apply these methods in controlled clinical trials to demonstrate the potential clinical utility of evaluating different markers via blood sampling. Servier will participate by supporting a post-doctorate position and in-kind contributions during the 5y duration of the program in WPs 0, 1, 2. In addition, a minor contribution via biostatistics in bioinformatics expertise will be proposed in WP3.

CANCER-ID Consortium

CANCER-ID consortium

CANCER-ID Workpackages

CANCER-ID Work Plan

EUROPA - NEWS

News from the European Comission

What's new in Health and Life Sciences? Click here for news from the European Commission.

Search
Top
Home
Menu

EU logo
imi Logo
efpia Logo

News Section

developed by TATAA Biocenter and the Institute of Biotechnology, BIOCEV. Read more

Social Media

LinkedIn Cancer-ID